HIF1A and neoplasm: A preclinical study discovered that, when BAP1 is mutated, the levels of HIF-1α are significantly reduced and suggested that the improved prognosis observed in PM with BAP1 mutations may be linked to the reduced HIF-1α levels in the tumor cell and in the microenvironment [52].